News

Covidien has completed the previously announced acquisition of Aspect Medical Systems for an aggregate consideration of approximately $210m, net of cash and short-term investments acquired. The tender offer

Ziopharm has presented positive interim data from the multicenter randomized Phase II trial of palifosfamide (Zymafos, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The randomized

Sagentia, a part of a consortium led by GlaxoSmithKline, is delivering a step change improvement in advanced secondary pharmaceutical manufacturing in the UK. The aim of the project

The endorsement comes less than a year after the vaccine’s first licensure and will accelerate global access to Synflorix. Jean Stephenne, CEO of GSK, said: “The vaccine helps

Halozyme has reported the insulin variability study results that demonstrate reduced intrasubject absorption variability for the combination of lispro, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro

Chimerix has presented updates on the development of the antiviral compound, CMX001, to the World Health Organization (WHO) and the Global Health Security Initiative (GHSI). CMX001 is a

DSM Pharmaceutical has entered into a manufacturing alliance with Galenix where DSM will be the preferred commercial scale manufacturing partner for Galenix commercial products on a global basis.

Under the alliance, Epic and its employees and consultants are and will continue using a portion of the Registrant’s facility located at New Jersey, for the purpose of

Daiichi Sankyo has launched a new Phase III trial of its anti-influenza agent, CS-8958. The company’s goal is to gain an influenza prevention indication in Japan. The trial